Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Charles Bluhm

Gastroenterology Birmingham, AL Medical Doctor

NPI 1306822705 CMS profile 149555

1 Independence Plz, Ste 900, Birmingham, AL 35209

Open in the dashboard

General payments

$7,481

420 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,350 paid to institutions, not to them · program year 2019

Through program year 2023, Charles Bluhm of Birmingham, AL is reported in the CMS Open Payments database as having received $7,481 across 420 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,350 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $13 1
2022 General $2,161 102
2021 General $1,889 120
2020 General $925 64
2019 General $2,493 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Bluhm
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Charles Bluhm were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Charles Bluhm Gastroenterology median Middle half National median
2019 $2,493 $417 $126–$1,100 $163
2020 $925 $224 $74–$624 $114
2021 $1,889 $352 $106–$1,054 $132
2022 $2,161 $448 $129–$1,270 $149
2023 $13 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $2,013 88 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,455 102 payments
  3. Pfizer Inc. $1,154 57 payments
  4. Janssen Biotech, Inc. $686 57 payments
  5. Gilead Sciences, Inc. $492 27 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $340 24 payments
  7. RedHill Biopharma Inc. $205 6 payments
  8. Intercept Pharmaceuticals, Inc. $195 13 payments
  9. Janssen Scientific Affairs, LLC $149 1 payment
  10. E.R. Squibb & Sons, L.L.C. $110 1 payment
  11. Other $682 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,446 419 payments
  2. Education $35 1 payment
Products named General payments · program years 2019–2023
  1. XIFAXAN $1,146 84 payments
  2. XELJANZ $1,140 56 payments
  3. STELARA $835 59 payments
  4. HUMIRA $796 41 payments
  5. LINZESS $356 26 payments
  6. CREON $353 16 payments
  7. Talicia $205 6 payments
  8. ZEPOSIA $200 7 payments
  9. SKYRIZI $199 4 payments
  10. OCALIVA $195 13 payments
  11. Other $2,031 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record